BAFNAPH

Unclassified

Bafna Pharmaceuticals Limited

₹480.00

+7.00(1.48%)
EMA 9: 469.85EMA 21: 452.00RSI: 63.9MACD: 21.79ATR: 10.38
Overlays
RSI (14)

Open

₹482.45

High

₹482.45

Low

₹473.00

Close

₹480.00

Volume

30,890

Bafna Pharmaceuticals Limited (BAFNAPH) last closed at ₹480 on 17 Nov 2026, 4.3% below its 52-week high. Price is above both the 50-day and 200-day averages. Volume in the last session was 3.3 times the 20-day average. The scanner currently flags Strong Uptrend Alignment.

1 week

+1.5%

1 month

+4.0%

3 months

+90.1%

52-week high

₹501.65

-4.3% from high

52-week low

₹94.77

Volume vs 20-day

3.30×

Active signals

Move is measured from the close on the first day
Strong Uptrend AlignmentBULLISH
Day 2 · since 13 Nov-0.4%

Signal history

Past five months · move is the close-to-close change while the signal was on
DatesSignalTypeLastedMove
13 NovVolume BreakoutBULLISH1d—
12 NovRSI Overbought ZoneNEUTRAL1d—
11 Nov – 13 Nov20-Day High BreakoutBULLISH3d-0.0%
05 Nov – 11 NovStrong Uptrend AlignmentBULLISH4d+7.8%
03 NovVolume BreakoutBULLISH1d—
28 Oct – 29 OctVolume BreakoutBULLISH2d+1.2%
27 Oct – 30 OctStrong Uptrend AlignmentBULLISH4d+1.2%
26 OctVolume BreakoutBULLISH1d—
16 Oct – 21 OctVolume BreakoutBULLISH3d-0.0%
24 Sept – 22 OctRSI Overbought ZoneNEUTRAL18d+31.7%
21 Sept – 25 Sept20-Day High BreakoutBULLISH5d+8.2%
02 Sept – 23 SeptStrong Uptrend AlignmentBULLISH15d+9.3%
01 SeptRSI Overbought ZoneNEUTRAL1d—
28 Aug – 02 Sept20-Day High BreakoutBULLISH3d+5.8%
24 Aug – 28 AugStrong Uptrend AlignmentBULLISH5d+14.4%
24 AugEMA Crossover (9/21)BULLISH1d—
21 AugEMA Death Cross (9/21)BEARISH1d—
11 AugStrong Uptrend AlignmentBULLISH1d—
10 Aug20-Day High BreakoutBULLISH1d—
28 Jul – 30 Jul20-Day High BreakoutBULLISH3d+4.0%
28 Jul – 10 AugRSI Overbought ZoneNEUTRAL10d+12.7%
24 Jul – 27 JulStrong Uptrend AlignmentBULLISH2d+2.0%
22 Jul – 23 JulRSI Overbought ZoneNEUTRAL2d+2.0%
20 Jul – 23 Jul20-Day High BreakoutBULLISH4d+6.1%
10 Jul – 21 JulStrong Uptrend AlignmentBULLISH8d+14.2%

Technical data for educational purposes only — not investment advice